News & Updates

Findings from the phase III ELATIVE^® trial demonstrate that the peroxisome proliferator-activated receptor (PPAR) agonist elafibranor improves fatigue in individuals with primary biliary cholangitis (PBC), with limited correlation with pruritus.

Growth hormone therapy appears to boost height and growth rate in girls with Turner Syndrome (TS) or growth hormone deficiency (GHD), with pronounced effect seen in the first year of treatment, according to a case-control study.

Women with opioid use disorder (OUD) treated with buprenorphine during pregnancy had significantly lower rates of adverse maternal and infant outcomes than those who did not receive treatment, according to a study presented at PAS 2025.

In critically ill patients with moderate-to-severe acute respiratory distress syndrome (ARDS), inhaled sedation with sevoflurane may lead to fewer ventilator-free days at day 28 and lower 90-day survival compared with sedation with propofol, according to the results of the phase III SESAR study.

IBP-9414, a live biotherapeutic product (LBP), delivers gastrointestinal (GI) and mortality benefits in very low birth weight (VLBW) infants (BW 500–1,500g) born between 23 and 32 weeks gestational age in the phase III Connection study presented at PAS 2025.

New drug applications approved by US FDA as of 16-30 April 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New drug applications approved by US FDA as of 1-15 May 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

An interim analysis of a real-world study reporting up to 10 years of follow-up data shows that teduglutide, a human glucagon-like peptide-2 analogue, can provide long-term reductions in parenteral nutrition and/or intravenous fluid (PN/IV) requirements and shorter time to achieve enteral autonomy in adults with short bowel syndrome-associated intestinal failure (SBS-IF).

In the treatment of adults with hospital-associated (HABP) or ventilator-associated bacterial pneumonia (VABP), the β-lactam/β-lactamase inhibitor combination imipenem/cilastatin/relebactam appears to be as good as piperacillin/tazobactam, with similar safety profiles, according to a phase III trial.